MedTrace Logo

Extension Study of BMN 044 in Duchenne Muscular Dystrophy (DMD)

NCT02958202 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2018-01-26

No results posted yet for this study

Summary

The aim of this study is to provide continuing access to BMN 044 treatment for subjects previously treated with BMN 044. The information gained from this study is expected to further characterize the efficacy and safety of BMN 044 over a longer treatment period.

Conditions

Interventions

DRUG

BMN 044 IV 6 mg/kg

DRUG

BMN 044 IV 9 mg/kg

DRUG

BMN 044 SC 6 mg/kg

Sponsors & Collaborators

Principal Investigators

  • Paulatsya Joshi · BioMarin Pharmaceutical

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
5 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • Belgium
  • Italy
  • Netherlands
  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02958202 on ClinicalTrials.gov